Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2005-12-20
2011-12-20
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C530S387100, C530S387300, C530S387900
Reexamination Certificate
active
08080247
ABSTRACT:
An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
REFERENCES:
patent: 5457038 (1995-10-01), Trinchieri et al.
patent: 5547852 (1996-08-01), Seller et al.
patent: 5648467 (1997-07-01), Trinchieri et al.
patent: 5780597 (1998-07-01), Gately et al.
patent: 5811523 (1998-09-01), Trinchieri et al.
patent: 5891680 (1999-04-01), Lieschke et al.
patent: 6086876 (2000-07-01), Karp et al.
patent: 6225117 (2001-05-01), Gately et al.
patent: 6300478 (2001-10-01), Trinchieri et al.
patent: 6338848 (2002-01-01), Leonard et al.
patent: 6495667 (2002-12-01), Bazan
patent: 6914128 (2005-07-01), Salfeld et al.
patent: 790255 (1997-08-01), None
patent: 433827 (1998-03-01), None
patent: 804581 (2001-09-01), None
patent: WO 90/05147 (1990-05-01), None
patent: WO 92/05256 (1992-04-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 97/15327 (1997-05-01), None
patent: WO 97/15327 (1997-05-01), None
patent: WO 99/37682 (1999-07-01), None
patent: WO 00/56772 (2000-09-01), None
patent: WO 01/19373 (2001-03-01), None
patent: WO 02/12500 (2002-02-01), None
patent: WO 02/097048 (2002-12-01), None
Gubler, et al., “Coexpression of Two Distinct Genes is Required to Generate Secreted Bioactive cytotoxic Lymphocyte Maturation Factor,” Proceedings of the National Academy of Science USA vol. 88, 4143-4147 (1991).
Gubler, et al., “Clonic and Expression of Cytotoxic Lymphocyte Maturation Factor a Heterodimeric Lymphokine that Potentiates NR LAK NA D T-Cell Responses,” Abstracts of the Journal of Cellular Biochemistry Supplement 15F 70 (1991).
Stern, et al., “Purification to Homogeneity and Partial Characterization of Cytotoxic Lymphocyte Maturation Factor From Human B-Lymphoblastoid Cells,” Proceedings of the National Academy of Science, 87: 6808-6812 (1990).
Gately, et al., “Regulation of Human Lymphocyte Proliferation by a Heterodimeric Cytokine IL-12,” The Journal of Immunology, 147: 874-882 (1991).
Chizzonite, et al., “IL-12 Monoclonal Antibodies Specific for the 40-KdA Subunit Block Receptor Binding and Biologic Activity on Activated Human Lymphoblasts,” 147: 1548-1556 (1991).
Chan, et al., “Introduction of Interferon Production by Natural Killer Cell Stimulatory Factor Characterization of the Responder Cells and Cynergy with Other Inducers,” Journal of Experimental Medicine, 173: 869-879 (1991).
D'Andrea, et al., “Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cell,” Journal of Experimental Medicine, 176: 1387-1398 (1992).
Neurath, et al., “Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in Mice,” The Journal of Experimental Medicine, 182: 1281-1290 (1995).
Carter, et al., “Production and characterization of Monoclonal Antibodies to Human Interleukin-12,” Hybridoma, 16: 363-369 (1997).
Valiante, et al., “Role of the Production of Natural Killer Cell Stimulatory Factor NKSF/IL-12) in the Ability of B Cell Lines to Stimulate T and NK Cell Proliferation,” Cellular Immunology, 145: 187-198 (1992).
Duchmann, et al., “Tolerance Towards Resident Intestinal Flora in Mice is Abrogated in Experimental Colitis and Restores by Treatment with Interleukin-1 or Antibodies to Interleukin-12,” European Journal of Immunology, 26: 394-398 (1996).
Kobayashi, et al., “Identification and Purification of Natural Killer Cell Stimulatory Factor (NKFS) a cytokine iwht Multiple Biologic Effects on Human Lymphocytes,” Journal of Experimental Medicine, 170: 827-845 (1989).
Trembleau, et al., “The Role of IL-12 in the Induction of Organ-Specific Autoimmune Diseases,” Immunology Today, 16(8): 383-386 (1995).
Ywalkar, et al., “Expression of interleukin-12 is increased in psoriatic skin,” Journal of Investigative Dermatology, 111(6): 1053-1057 (1998).
Swiss-Prot Accession No. P29459, Mar. 3, 2009.
Kauffman, et al., The Journal of Investigative Dermatology, 123(6): 1037-1044 (2004).
Li, et al., “Anti-IL-12 p40 mAb prevents diabetes onset by inducing active immune suppression,” FASEB Journal, 17(7): C270 (2003).
Mannon, et al., “Anti-Interleukin-12 Treats Active Crohn's Disease,” Gastroenterology, 26(4): A22-A23 (2004).
Mosby, et al., Abstracts 1230-1260, Journal of Allergy and Clinical Immunology, 99(1): S301-S400 (1997).
Supplemental EP Search Report dated Mar. 20, 2009.
Amit, et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution,” Science, 233(4765): 747-753 (1986).
Eck, et al., “Chapter 5—Scope of Gene Therapy,” Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill (1996).
Lonberg, et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, 368: 856-859 (1994).
Panka, et al., “Variable Region Framework Differences Result in Decreased or Increased Affinity ofVariant Anti-Digoxin Antibodies,” Proceedings of the National Academy of Sciences of he United States of America, 85(9): 3080-3084 (1988).
PCT International Search Report dated Jun. 1, 2007.
Supplementary European Search Report dated Mar. 20, 2009.
Swiss-Prot Accession No. P29460, Apr. 1, 1993.
Giles-Komar Jill
Heavner George
Knight David
Luo Jinquan
Peritt David
Dichter Eric
Janssen Biotech, Inc.
Mertz Prema
LandOfFree
Anti-IL-12 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-12 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-12 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305387